Literature DB >> 15937959

Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2.

Nadège Presneau1, Ken Dewar, Vince Forgetta, Diane Provencher, Anne-Marie Mes-Masson, Patricia N Tonin.   

Abstract

Loss of heterozygosity (LOH) analysis was performed in epithelial ovarian cancers (EOC) to further characterize a previously identified candidate tumor suppressor gene (TSG) region encompassing D17S801 at chromosomal region 17q25.1. LOH of at least one informative marker was observed for 100 (71%) of 140 malignant EOC samples in an analysis of 6 polymorphic markers (cen-D17S1839-D17S785-D17S1817-D17S801-D17S751-D17S722-tel). The combined LOH analysis revealed a 453 kilobase (Kb) minimal region of deletion (MRD) bounded by D17S1817 and D17S751. Human and mouse genome assemblies were used to resolve marker inconsistencies in the D17S1839-D17S722 interval and identify candidates. The region contains 32 known and strongly predicted genes, 9 of which overlap the MRD. The reference genomic sequences share nearly identical gene structures and the organization of the region is highly collinear. Although, the region does not show any large internal duplications, a 1.5 Kb inverted duplicated sequence of 87% nucleotide identity was observed in a 13 Kb region surrounding D17S801. Transcriptome analysis by Affymetrix GeneChip and reverse transcription (RT)-polymerase chain reaction (PCR) methods of 3 well characterized EOC cell lines and primary cultures of normal ovarian surface epithelial (NOSE) cells was performed with 32 candidates spanning D17S1839-D17S722 interval. RT-PCR analysis of 8 known or strongly predicted genes residing in the MRD in 10 EOC samples, that exhibited LOH of the MRD, identified FLJ22341 as a strong candidate TSG. The proximal repeat sequence of D17S801 occurs 8 Kb upstream of the putative promoter region of FLJ22341. RT-PCR analysis of the EOC samples and cell lines identified DKFZP434P0316 that maps proximal to the MRD, as a candidate. While Affymetrix technology was useful for initially eliminating less promising candidates, subsequent RT-PCR analysis of well-characterized EOC samples was essential to prioritize TSG candidates for further study. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937959     DOI: 10.1002/mc.20096

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  23 in total

1.  NHERF1/EBP50 in Breast Cancer: Clinical Perspectives.

Authors:  Antonia Bellizzi; Andrea Malfettone; Rosa A Cardone; Anita Mangia
Journal:  Breast Care (Basel)       Date:  2010-04-09       Impact factor: 2.860

2.  Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene.

Authors:  Narayan Shivapurkar; Victor Stastny; Naoki Okumura; Luc Girard; Yang Xie; Clemens Prinsen; Frederik B Thunnissen; Ignacio I Wistuba; Bogdan Czerniak; Eugene Frenkel; Jack A Roth; Triantafillos Liloglou; George Xinarianos; John K Field; John D Minna; Adi F Gazdar
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 3.  Cytoglobin: biochemical, functional and clinical perspective of the newest member of the globin family.

Authors:  Urszula Oleksiewicz; Triantafillos Liloglou; John K Field; George Xinarianos
Journal:  Cell Mol Life Sci       Date:  2011-07-09       Impact factor: 9.261

4.  Promotion of liver and lung tumorigenesis in DEN-treated cytoglobin-deficient mice.

Authors:  Le Thi Thanh Thuy; Takashi Morita; Kayo Yoshida; Kenichi Wakasa; Masashi Iizuka; Tomohiro Ogawa; Mami Mori; Yumiko Sekiya; Shinobu Momen; Hiroyuki Motoyama; Kazuo Ikeda; Katsutoshi Yoshizato; Norifumi Kawada
Journal:  Am J Pathol       Date:  2011-06-02       Impact factor: 4.307

Review 5.  Cytoglobin in tumor hypoxia: novel insights into cancer suppression.

Authors:  Sankalpa Chakraborty; Rince John; Alo Nag
Journal:  Tumour Biol       Date:  2014-05-10

6.  Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer.

Authors:  R J Shaw; M M Omar; S Rokadiya; F A Kogera; D Lowe; G L Hall; J A Woolgar; J Homer; T Liloglou; J K Field; J M Risk
Journal:  Br J Cancer       Date:  2009-07-07       Impact factor: 7.640

7.  Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.

Authors:  Karen M Chisholm; Barbara A Goff; Rochelle Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Cancer Genet Cytogenet       Date:  2008-05

8.  Expression and biological role of cytoglobin in human ovarian cancer.

Authors:  Haiying Chen; Xia Zhao; Tao Meng
Journal:  Tumour Biol       Date:  2014-04-17

9.  RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome.

Authors:  Diana C Blaydon; Sarah L Etheridge; Janet M Risk; Hans-Christian Hennies; Laura J Gay; Rebecca Carroll; Vincent Plagnol; Fiona E McRonald; Howard P Stevens; Nigel K Spurr; D Timothy Bishop; Anthony Ellis; Janusz Jankowski; John K Field; Irene M Leigh; Andrew P South; David P Kelsell
Journal:  Am J Hum Genet       Date:  2012-01-19       Impact factor: 11.025

10.  ΔNp63 targets cytoglobin to inhibit oxidative stress-induced apoptosis in keratinocytes and lung cancer.

Authors:  A Latina; G Viticchiè; A M Lena; M C Piro; M Annicchiarico-Petruzzelli; G Melino; E Candi
Journal:  Oncogene       Date:  2015-06-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.